High materiality7/10
Cullinan Therapeutics price target raised to $40 from $39 at BTIG
Why it may matterVerify against the original reporting
upgrade
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst BTIG raises CGEM target to $40; current price $20.73; upside ~93%.
- Target: $40; Price: $20.73; Upside ~93%
- Firm: BTIG
Key facts
- 01
Target: $40
- 02
Posted price: $20.73
- 03
Analyst firm: BTIG
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.